Immunocore And MedImmune Win The SCRIP Award For Best Partnership Alliance 2014
(Oxford, UK, 10th December 2014) Immunocore Limited, a leading biotechnology company focused on developing ImmTACs, novel first-in-class biological drugs to treat cancer and viral disease, has won the Partnership Alliance SCRIP Award 2014 together with its partner, MedImmune, the global biologics research and development arm of AstraZeneca.
The prestigious industry Award recognizes MedImmune’s and Immunocore’s achievements in closing a major strategic partnership agreement at the end of 2013 to research and develop novel cancer therapies using Immunocore’s ImmTAC technology.
Under the terms of the agreement, Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets. AstraZeneca and MedImmune have the right to further develop and commercialise ImmTAC products to add to their immunotherapy portfolio. Immunocore received an upfront payment of $20 million per programme and the company is eligible to receive up to $300 million in development and commercial milestone payments for each target programme and significant tiered royalties if the programmes are successful.
Eva-Lotta Allan, Chief Business Officer of Immunocore, commented: “We are delighted to have won the SCRIP Award 2014 together with our partner MedImmune for the Best Partnership Alliance. It is a pleasure to work with the MedImmune team and we look forward to together advancing ImmTAC’s towards the clinic.”
Reginald Seeto, Vice President, Head of Partnering and Strategy, MedImmune, added: “We are very pleased to have received the recognition from the SCRIP Award Judging panel for this creative partnership alliance with Immunocore. Immunocore has a strong track record with its innovative ImmTAC technology, and presents a significant opportunity for us to achieve treatment breakthroughs in the area of immunotherapy.”
Immunocore’s most advanced ImmTAC programme, IMCgp100, is currently in Phase IIa clinical trials in the United States and United Kingdom, in patients with late-stage malignant melanoma.
-ENDS-
Contact
Margaret Henry
Head of PR
Immunocore Ltd, UK
T: + 44 (0) 1235 430036
M: + 44 (0) 7710 304249
E: margaret.henry@immunocore.com
Notes for editors
About Immunocore
Founded in 2008, Immunocore Ltd is a privately owned, clinical-stage biotechnology company developing a highly innovative platform technology that generates novel drugs called ImmTACs for the treatment of cancer and viral infection. Immunocore traces its roots to Avidex Ltd, founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Receptor technology invented by the founder and chief scientist, Dr Bent Jakobsen.
Immunocore has major discovery collaborations ongoing with leading pharmaceutical companies, Genentech, GlaxoSmithKline and MedImmune, the biologics division of AstraZeneca, and a co-discovery and co-development partnership with Eli Lilly. Immunocore was listed in the top 15 private biotech firms globally for 2013 by Fierce Biotech and named Best Biotech Dealmaker of 2013 at the OBN Awards. The company has over 125 staff and is located in Abingdon, Oxfordshire. For more information, please visit www.immunocore.com
About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. For more information, please visit www.medimmune.com
Help employers find you! Check out all the jobs and post your resume.
Under the terms of the agreement, Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets. AstraZeneca and MedImmune have the right to further develop and commercialise ImmTAC products to add to their immunotherapy portfolio. Immunocore received an upfront payment of $20 million per programme and the company is eligible to receive up to $300 million in development and commercial milestone payments for each target programme and significant tiered royalties if the programmes are successful.
Eva-Lotta Allan, Chief Business Officer of Immunocore, commented: “We are delighted to have won the SCRIP Award 2014 together with our partner MedImmune for the Best Partnership Alliance. It is a pleasure to work with the MedImmune team and we look forward to together advancing ImmTAC’s towards the clinic.”
Reginald Seeto, Vice President, Head of Partnering and Strategy, MedImmune, added: “We are very pleased to have received the recognition from the SCRIP Award Judging panel for this creative partnership alliance with Immunocore. Immunocore has a strong track record with its innovative ImmTAC technology, and presents a significant opportunity for us to achieve treatment breakthroughs in the area of immunotherapy.”
Immunocore’s most advanced ImmTAC programme, IMCgp100, is currently in Phase IIa clinical trials in the United States and United Kingdom, in patients with late-stage malignant melanoma.
-ENDS-
Contact
Margaret Henry
Head of PR
Immunocore Ltd, UK
T: + 44 (0) 1235 430036
M: + 44 (0) 7710 304249
E: margaret.henry@immunocore.com
Notes for editors
About Immunocore
Founded in 2008, Immunocore Ltd is a privately owned, clinical-stage biotechnology company developing a highly innovative platform technology that generates novel drugs called ImmTACs for the treatment of cancer and viral infection. Immunocore traces its roots to Avidex Ltd, founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Receptor technology invented by the founder and chief scientist, Dr Bent Jakobsen.
Immunocore has major discovery collaborations ongoing with leading pharmaceutical companies, Genentech, GlaxoSmithKline and MedImmune, the biologics division of AstraZeneca, and a co-discovery and co-development partnership with Eli Lilly. Immunocore was listed in the top 15 private biotech firms globally for 2013 by Fierce Biotech and named Best Biotech Dealmaker of 2013 at the OBN Awards. The company has over 125 staff and is located in Abingdon, Oxfordshire. For more information, please visit www.immunocore.com
About MedImmune
MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. For more information, please visit www.medimmune.com
Help employers find you! Check out all the jobs and post your resume.